Audenz (influenza A (H5N1) monovalent vaccine adjuvanted) / CSL Behring - LARVOL DELTA

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study (ASH 2024) - "This study also emphasizes the clinical impact of BKVD, demonstrating a significant association with increased risk of NRM after allo-HCT. These findings highlight the need to develop anti-BK virus therapeutics, including cellular therapies, to improve patient outcomes."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Transplantation

Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands (ISPOR-EU 2025) - "With an assumed rVE of 13.7%, replacing SD-IV with aIV in adults aged ≥60 years in the Netherlands would have been a cost-effective strategy, with ICERs consistently below the commonly accepted willingness-to-pay threshold."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Influenza • Respiratory Diseases

ECAS01 Early Career Scientists workshop - Communicating science - invitation only - with the support of CSL Seqirus and Sanofi (ESWI 2025) - No abstract available

Infectious Disease

Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults (ESWI 2025) - No abstract available

Clinical • P1/2 data • Infectious Disease • Novel Coronavirus Disease

ECAS02 Early Career Scientists event and panel discussion "Life after Phd" - invitation only - with the support of AstraZeneca, CSL Seqirus and Sanofi (ESWI 2025) - No abstract available

Infectious Disease

SAT07 Satellite Symposium organised by CSL Seqirus: Addressing the evolving influenza landscape: a public health imperative (ESWI 2025) - No abstract available

Infectious Disease • Influenza

Immunogenicity and safety of high dose formulations of mf59-adjuvanted cell-derived influenza vaccine in adults aged 50 years and older: two phase 2 randomised controlled trials (ESWI 2025) - No abstract available

Clinical • P2 data • Infectious Disease • Influenza

Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States (ESWI 2025) - No abstract available

Infectious Disease • Influenza

Immunogenicity of Homologous or Heterologous Booster Vaccinations with MF59-Adjuvanted, Cell Culture–Derived H5N8 or H5N6 Influenza Vaccines in Healthy Subjects Aged ≥18 Years (ESWI 2025) - No abstract available

Preclinical • Infectious Disease • Influenza

Comparable Vaccine Effectiveness of Adjuvanted and High-Dose Influenza Vaccines in Preventing Test-Confirmed Influenza Outcomes, including Hospitalization, in Overall and High-Risk Older Adults: A Test-Negative Design Study During 2022-2023 and 2023-2024 (IDWeek 2025) - No abstract available

Clinical • Infectious Disease • Influenza

Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg-Based Influenza Vaccines During the 2023–2024 Season in the United States (IDWeek 2025) - No abstract available

Infectious Disease • Influenza

Safety of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-Adjuvanted Cell Culture-derived Influenza Vaccine in Healthy Subjects ≥18 Years of Age (IDWeek 2025) - No abstract available

Preclinical • Infectious Disease • Influenza

Immunogenicity of two vaccinations of an H5N8 MF59-Adjuvanted Cell Culture-derived Influenza Vaccine (aH5N8c) in Healthy Subjects ≥18 Years of Age (IDWeek 2025) - No abstract available

Preclinical • Infectious Disease • Influenza

The Impact of Low Influenza Immunization Rates on U.S. HealthCare Resources. A Modelling Assessment. (IDWeek 2025) - No abstract available

Infectious Disease • Influenza

Quantifying the Economic Consequences of Low Influenza Immunization Rates in the U.S. (IDWeek 2025) - No abstract available

Infectious Disease • Influenza

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions. (PubMed, Vaccines (Basel)) - " The aH5N1 vaccine had a clinically acceptable safety and tolerability profile with an AE profile comparable to that observed in previous aH5N1 studies. These findings support the viability of aH5N1 as a pre-pandemic influenza vaccine for the immunization of at-risk individuals when an antigenically matched pandemic influenza vaccine is not yet available."

Journal • Geriatric Disorders • Hematological Disorders • Infectious Disease • Influenza • Respiratory Diseases

A Randomized Study to Evaluate the Efficacy of a Cell-Based Quadrivalent Influenza Vaccine Compared to a Non-Influenza Vaccine in Children 6 Months to 47 Months of Age (PAS 2025) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

Burden of Severe ANCA Associated Vasculitis in Australia via Real-World Usage of Rituximab (ISPOR-EU 2024) - " Patients diagnosed with severe AAV in Australia are initially treated with one of two treatments as induction therapy, rituximab (RTX) or cyclophosphamide (CYC)... The incidence of patients with severe AAV treated in Australia is likely to be higher than previous studies have shown."

Clinical • Real-world • Real-world evidence • ANCA Vasculitis • Rare Diseases • Vasculitis

Update and narrative review of avian influenza (H5N1) infection in adult patients. (PubMed, Pharmacotherapy) - "This includes a cell-based vaccine approved by the FDA for people aged 6 months and older who are at higher risk of exposure to the H5N1 virus called Audenz...Neuraminidase inhibitors are the mainstay of the avian influenza treatment and includes oseltamivir, peramivir, and zanamivir. Baloxavir marboxil is a cap-dependent endonuclease inhibitor. This clinical review aims to highlight the background, epidemiology, clinical presentation, complications and current treatment and prevention strategies for avian influenza H5N1."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Cost-Effectiveness of Difelikefalin Compared to Best Supportive Care for Treatment of Chronic Kidney Disease-Associated Pruritus in Australia (ISPOR-EU 2024) - "Difelikefalin for treatment of CKD-aP in haemodialysis patients is an effective and cost-effective intervention relative to current practice in Australia. Conflict of interest: Study sponsored by CSL Seqirus Australia."

Cost effectiveness • HEOR • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

Title TBC (WVCE 2024) - No abstract available

From policy to practice: navigating the COVID-19 vaccination landscape in Europe (WVCE 2024) - No abstract available

Infectious Disease • Novel Coronavirus Disease

Avian influenza: A case study for vaccinating livestock (WVCE 2024) - "- The impact of vaccination on managing disease outbreaks - what have we learnt from French programs?- The economic impact of vaccination on trade- Matching our vaccines to the circulating strains- Monitoring disease epidemiology and spill over to mammals, will this be the next human pandemic?- Does livestock vaccination protect human health?"

Case study • Clinical • Infectious Disease • Influenza • Respiratory Diseases

Biothreats & Disease X Workshop [AM2] (WVCE 2024) - "Sponsored by: Pfizer"

Industry Symposium: CSL Seqirus Strengthening Influenza Protection: A symposium on paediatric, pandemic and pioneering solutions (ISIRV-OPTIONS XII 2024) - "Sponsored by CSL Seqirus"

Infectious Disease • Influenza • Pediatrics • Respiratory Diseases